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040 Her-2/Neu Staining in Osteosarcoma: Association with 
Increased Risk of Metastasis
Holly Zhou, Rob Goldsby, R. Lor Randall, Lynn Smith, Cheryl 
M. Coffin
Departments of Pathology, Pediatrics, Orthopedics, and Radiation 
Oncology, University of Utah
Objective: Her-2/Neu  expression  in  high  grade  osteosarcomas
(OSC) has been proposed as an indicator of poor prognosis. This
study correlates Her-2/ Neu staining in OSC with tumor progres-
sion and metastasis.
Methods: Her-2/Neu expression in 22 pre-treatment OSC and 12
pulmonary metastatic OSC was assessed by standard immunohis-
tochemical techniques on formalin-fixed paraffin embedded tissue.
The Her-2/Neu staining pattern, outcome and pulmonary metas-
tases were analyzed.
Results: 10/22 pretreatment OSC displayed cytoplasmic Her-2/
Neu reactivity in more than 25%  of tumor cells.  Among these,
70% (7/10) patients had pulmonary metastases (4 at presentation,
3 later). In addition, focal cytoplasmic Her-2/Neu reactivity with
more intense staining in foci with  chondroblastic differentiation
was  identified  in  7/22  pre-treatment  OSC.  5/7  patients  in  this
group had pulmonary metastases in a minimal follow-up of 4 years.
The pattern of Her-2/Neu staining in pulmonary metastatic OSC
is identical to that in primary OSC.
Conclusion: Cytoplasmic staining of Her-2/Neu in pre-treatment
OSC correlates with increased risk of pulmonary metastasis. The
Her-2/Neu positive cells may represent a chemoresistant, biologi-
cally aggressive subpopulation in OSC.
087 Reconstruction of the Pelvis Following Resection of 
Tumors about the Acetabulum
R. L. Satcher, Jr.1, R. J. O’Donnell1, J. O. Johnston1
1University of California, San Francisco Department of Orthopaedic 
Surgery UCSF Comprehensive Cancer Center Orthopaedic Oncology 
Service 1701 Divisadero Street Suite 280, 2The Permanente Medical 
Group, Inc. Department of Musculoskeletal Oncology 1200 El Camino 
Real
Objective: Periacetabular resections for primary malignancies and
metastatic disease require reconstruction to restore weight-bearing
along anatomic axes. Without reconstruction, patients are unable
to ambulate independently, and are left with a disfigured pelvis and
a shortened limb. This abstract describes a reconstruction tech-
nique using rebar, cement, and autoclaved autografting, in combi-
nation  with  total  hip  arthroplasty,  after  resection  of  primary
sarcomas of the pelvis.
Methods: This  study retrospectively  reviewed the  results  of 15
patients at 2 institutions who had surgery by the same surgeons.
The  patients  had  primary  malignant  tumors  of  the  pelvis,  and
underwent limb-sparing resections between 1985 and 2000. The
surgical method utilized threaded Steinman pins with bone cement
to fill areas of bone loss that could not be reconstructed with auto-
claved autograft. A constrained polyethylene acetabular compo-
nent is  cemented into this  bed. Three outcome measures  were
evaluated: survival, function, and pain.
Results: Twelve patients had chondrosarcoma, two had alveolar
soft parts sarcoma, and one had osteosarcoma. According to the
Enneking-Dunham classification, there were 10 type II resections,
and one each of types I, I/II, I/II/III, II/III, and III. There were 9
living and 6 deceased patients. For living patients, follow-up aver-
aged  75  months  (range 26  to  164)  and for  deceased  patients,
follow-up averaged 28  months  (range 12  to 46). For chondro-
sarcoma patients, the local recurrence rate was 25% (3/12). All
patients except one were ambulatory; 9 were able to walk without
an assistive device. According to the MSTS Rating System, scores
averaged 23/30 for living patients (range 10 to 27). Eleven patients
were community ambulators and narcotics were used occasionally
by only 2 patients. Surgical complications included 2 prosthetic
dislocations, 2 wound hematomas, and 1 perioneal nerve palsy.
Conclusion: Reconstruction  of  massive  pelvic  defects  with
cement,  rebar,  autoclaved  autograft,  and  constrained  total  hip
replacements  is a technique that compares favorably with  other
methods that have been reported. Functional outcome in terms of
ambulatory capacity is substantially  better  than has been noted
historically. The time required for independent gait is similar to
recovery  from  routine  total  hip  arthroplasty.  Moreover,  this
method limits leg length discrepancy, while producing a favorable
cosmetic result.
020 Curative Treatment and Effective Palliation with 
Hemipelvectomy—A Useful Operation: Modern Concepts 
Based on 20 Years of Experience
James C Wittig1, Jacob Bickels2, Felasfa Wodajo1, Kristen L. 
Kellar-Graney1, Yehuda Kollender2, Isaac Meller2, Martin M 
Malawer1
1Division of Orthopedic Oncology Washington Cancer Institute 
Washington Hospital Center, 2National Unit of Orthopedic Oncology 
Tel-Aviv Sourasky Medical Center
Objective: The purpose of this study is to analyze the indications,
describe  the  surgical  technique, and report the  oncological and
functional outcomes and complications associated with hemipel-
vectomy.
Methods: Retrospective  analysis of 44 patients  (23  females,  21
males) treated with a hemipelvectomy between 1981  and 2001.
Diagnoses: 14 pelvic and 9 proximal femur bone sarcomas, 3 met-
astatic carcinomas to the pelvis, 8 thigh soft tissue sarcomas, 1 soft
tissue metastatic carcinoma, and 9 palliative (infection, trauma).
Types of Hemipelvectomy: 13 classical, 21 modified, 6 extended
and 4 anterior flap. Tumor Stages: IB (2), IIB (20), III (8), benign
aggressive (1), stage IV lymphoma (2), metastatic carcinomas (5).
Results: Follow-up: 2 mos-181  mos (mean: 50.4 mos). There
were 19 patients NED, 2 AWD, and 23 patients deceased. In the
subset  of  patients  with  tumors  (n=35), twelve patients  (34%)
were alive without evidence of disease. There was one local recur-
rence. All patients treated for infection, and trauma were success-
fully  treated.  Thirty-nine  patients  (89%)  were  pain  free.  All
patients, except one patient, were ambulatory with crutches; two
patients  used a prosthesis.  Four (10%) patients  reported mild
phantom limb pain. The most common complication was skin
flap necrosis (8 patients); all were treated successfully with surgi-
cal debridement. Additional complications included: one perirec-
tal  abscess  and  two  patients  with  urinary  and/or  erectile
problems. There were no deaths due to intraoperative hemor-
rhage.
Conclusion: We recommend hemipelvectomy for curative treat-
ment and palliation of selected pelvic and peripelvic tumors. It is a
useful procedure when no limb sparing surgical option exists. It is
also effective in certain instances of life threatening pelvic/lower
extremity infection and trauma. Skin flap necrosis can be managed
effectively. The incidence and severity of postoperative causalgia
syndrome and urinary/bowel problems is minor. Survivors resume
a functional life.S10 CTOS  abstracts
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016 Bugged Out? Infection and Endoprosthetic 
Replacements
Lee M Jeys, Raj Suneja, Vishnu Prasad, Robert Grimer, Simon 
R Carter, Roger Tillman
Royal Orthopaedic Hospital Oncology Service, Royal Orthopaedic 
Hospital
Objective: Endoprosthetic replacement (EPR) following surgical
excision of bone tumours is now common practice. They allow
rapid restoration of function, are readily available and have good
long term functional scores. However, one of the major complica-
tions  of  EPRs  is  infection  and this  can  have  disastrous  conse-
quences. It requires prolonged and expensive treatment, and may
result in decreased function, with even a possibility of amputation.
This paper aims to investigate the cause of infection, management
and its sequelae.
Methods: Prospective data is collected on all patients seen in our
centre and stored on a database. Information collected includes
demographic data, diagnosis, site, treatment (including adjuvant),
complications,  and outcomes.  Records  of  over  10,000  patients
have been kept over 34 years. Data was analysed on all patients
who had undergone EPRs, in order to identify any infection, its
management and outcome. Factors such as operating time, intra-
operative blood loss, adjuvant therapy, type of prosthesis (extend-
able  or  standard)  were  investigated.  Outcomes  of  treatment
options were also evaluated.
Results: Over 1260 patients have undergone EPR in our center
over 34 years. This gives a total follow up time of over 6500 patient
years. Over 200 (16%) patients have been diagnosed with deep
infection in their prosthesis (as defined by a positive culture in a
clinically  infected  prosthesis)  and  of  these  38  (25%)  required
amputations for uncontrollable infection. The commonest proce-
dure for infection control was 2 stage revision. Common organisms
involved  in  infection  were  Staphylococcus  aureus,  Streptococcus
viridians and epidermidis.
Conclusion: Infections are one of the most serious complications
to affect EPRs. Treatment can be difficult and prolonged. If early
infection is diagnosed immediate lavage and IV antibiotics are rec-
ommended. Otherwise 2 stage revision is the only reliable method
for limb salvage. Prevention must be the key to reducing the inci-
dence of this serious complication.
056 Margin Width has Prognostic Significance for 
Extremity / Truncal Sarcoma
Mark D. McKee, Dong Feng Liu, Deborah Driscoll, John 
J. Brooks, John F. Gibbs, William G. Kraybill
Roswell Park Cancer Institute
Objective: Following resection of soft tissue sarcoma (STS), the
presence of positive margins is associated with local recurrence and
inconsistently reported to predict distant failure or shorter survival.
Margin width is not emphasized in treatment planning or outcome
analyses. We examined the prognosis of patients with wide margins
(10+ mm), close margins (1-9 mm), and positive margins (0 mm).
Methods: Patients  undergoing  resection  of  primary  extremity/
truncal sarcoma were evaluated for clinico-pathological features
predicting outcome via retrospective review of charts and tumor
specimens. Only patients with residual tumor available for patho-
logic review were included.
Results: Among 111 patients, tumors were predominantly inter-
mediate to high grade (95), larger or equal to 5 cm in size (84), and
deep (90). Treatment included wide excision or amputation for
110. High risk patients with positive or negative margins received
adjuvant radiation (RT) (42 patients) and/or adjuvant chemother-
apy (CT) (37 patients). Margin status: The margin width was 10+
mm in 53 patients (48%), 1-9 mm in 45 patients (40%), and 0mm
in 13 patients (12%). Margins of 0 mm and 1-9 mm were more
common among tumors of larger size (p=.008), and deep location
(p=.01). More grade 1 tumors had 0 mm margins, and more grade
2 tumors had 10+ mm margins (p=.02). Age, gender, stage, site,
necrosis, mitotic rate, resection type, and RT were similar among
groups. Multivariate analysis: In a model including age, gender,
grade, size, depth, stage, histology, tumor location, type of resec-
tion, RT, CT, and margin status, independent predictors of poor
disease-free survival included higher grade (p=.009), larger size
(p=.003),  and  decreased  margin  width  (p=.007).  Independent
predictors of poor overall survival included higher grade (p=.001),
larger size (p=.002), and deep location (p=.05).
106 Gene-Expression Profiles in Chondrosarcomas and 
Chordomas
Thomas F. DeLaney1, Brian Seed2, Ramnik Xavier2, Andrew 
L. Rosenberg3, G. Petur Nielsen3, Francis J. Hornicek4, Norbert 
J. Liebsch1, John E. Munzenrider1, Herman D. Suit1
1Dept. of Radiation Oncology, Massachusetts General Hospital, 2Dept. 
of Molecular Biology, Massachusetts General Hospital, 3Dept. of 
Pathology, Massachusetts General Hospital, 4Dept. of Orthopedic 
Surgery, Massachusetts General Hospital
Objective: Outcome analysis of more than 200 patients each with
low grade chondrosarcoma and chordoma of the skull base follow-
ing high dose proton beam radiation treatment has revealed a very
large  difference  between  these  two  pathological  tumor  types.
Namely,  the  10  year  local  control  results  were  95%  and 45%
respectively. These tumors were of approximately the same size,
anatomic site and received the same radiation doses. Further, they
were managed by the same clinicians and physicists. We hypothe-
size that there are important differences in the radiation sensitivity
of the constituent tumor cells of these tumors. Our research plan is
to assess differences in expression profiles of those genes involved
in repair of DNA and angiogenesis. This information is expected
to  help  explain  the  differences  in  radiation  sensitivity  of  these
tumors.
Methods: RNA from samples of 10 chordomas and 10 chondro-
sarcomas will be compared with a microarray of complementary
DNA clones which included panels of genes known to be involved
in DNA repair or angiogenesis. Statistical analyses will be used to
identify a set of genes that could distinguish the very different clin-
ical response of chondrosarcomas and chordomas to radiotherapy.
Results: Tumor samples from 10 patients with chordomas and 10
patients with chondrosarcomas have been obtained. Initial RNA
extraction has been successful and cDNA arrays of genes associ-
ated with angiogenesis, cellular stress, and cancer metastasis have
been  designed.  Gene  expression  profiles  for  the  tumors  are  in
progress. Results of the analysis will be presented.
Conclusion: Gene expression profiles  for chondrosarcomas  and
chordomas may elucidate differences in clinical behavior.
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131 Inhibition of PDGF Receptor Tyrosine Kinases
By STI-571 In Human Soft-Tissue Sarcoma
Jonathan C. Trent, Jonathan Hannay, Lan Li, Shreyaskumar 
Patel, Robert S. Benjamin, Raphael E Pollock, Di-Hua Yu
The University of Texas, M. D. Anderson Cancer Center
Objective: Abnormalities  in  signal  transduction  pathways  are
common in soft tissue sarcomas. Because these are rare tumors
that also respond poorly to standard chemotherapy and bear a
50% 5-year mortality rate, we investigated the possible therapeu-
tic benefits of the tyrosine kinase inhibitor STI-571 in soft-tissueCTOS  abstracts S11
sarcomas. The objectives of our laboratory investigation are (1)
to characterize the anti-tumor activity of STI-571 alone and with
doxorubicin, in vitro; (2) to determine whether the inhibition of
signal transduction molecules by STI-571 causes cell cycle arrest,
induction of apoptosis, inhibition of the invasive phenotype and/
or abrogation of angiogenesis; (3) to determine the anti-tumor
activity of STI-571 alone and in combination with doxorubicin in
human tumor xenografts.
Methods: We initially screened 15 soft-tissue sarcoma cell lines
for expression of PDGF-R. Western blot analysis identified 12 that
expressed  high  levels and 3 that  expressed  low levels.  We have
investigated the efficacy of STI-571 (0.4-20micromolar) alone and
combined with doxorubicin(0.1-10micromolar) in the rhabdomyo-
sarcoma cell line A204. Kit, PDGF-R, Map kinase, and Akt-1 sig-
naling were evaluated by immunoblot. Proliferation assays were
performed with a 48 hour exposure to incremental drug concentra-
tions and viability assessed by MTS reagent. TUNEL assay and
cell  cycle analysis were performed by flow cytometry. Soft agar
colony formation assay was performed to assay for anchorage inde-
pendent growth. Endothelial cell proliferation rate in response to
conditioned  media  from  STI-571  treated  A204  cells  will  be
assessed. Zymogen invasion assay will be performed as an in vitro
assessment of the invasive phenotype. SCID mice will be injected
with A204 cells prior to treatment with doxorubicin alone, STI-
571 alone, or the combination.
Results: Sarcoma cells treated with doxorubicin, STI-571, or the
combination, exhibit a 40%, 20%, and 60% absolute reduction in
percent viable cells, respectively. STI-571 increased the  relative
percentage of cells  in G1 (by 57%)  and decreased S-phase  (by
63%) when compared to untreated cells. Apoptosis increased from
4% to 15% after treatment. Doxorubicin treatment did not induce
cell cycle arrest, but induced apoptosis from a baseline of 5% to
50%.  STI-571  treatment  resulted  in  a  decrease  (48%)  in  the
number of colonies established by soft agar growth. Endothelial
cell proliferation assay, Zymogen invasion assay, and in vivo ther-
apy with STI-571 experiments are ongoing.
Conclusion: In vitro results suggest an additive, non-overlapping
effect  of  doxorubicin+STI-571,  indicating  a  potentially  useful
combination. Together, these efforts should result in new mecha-
nism-driven therapies that are efficacious in soft-tissue sarcoma.
130 Expression Profiling of Osteosarcoma Biopsies and 
Metastases with cDNA Microarrays
Luca Sangiorgi1, Giuliana Alessandra Gobbi1, Enrico Lucarelli1, 
Francesca Scrimieri1, Piero Picci1, Paul Meltzer1
1Lab. Oncology Research, Rizzoli Orthopedic Institute, 2Section of 
Molecular Genetics, Cancer Genetics Branch, National Human 
Genome Research Institute, National Institutes of Health
Objective: Expression profiling with cDNA microarrays offers the
possibility to determine global patterns of gene expression tumor
specimens which can be used for diagnostic classification, the iden-
tification of subsets as well as the elucidation of oncogenic path-
ways and novel therapeutic targets.
Methods: We  have  explored  the  potential  of  applying  this
technology to osteogenic sarcoma. 14 primary osteosarcomas and
8  osteosarcoma  pulmonary  metastases  were  analyzed  by
hybridiation to cDNA microarrays. For comparison, five Ewing’s
sarcoma specimens, and normal lung tissue were also analyzed.
Results: We  determined  that  high  quality  results  could  be
obtained from osteosarcoma specimens despite the presence of
extracellular matrix material in these specimens. A distinct pat-
tern of gene expression for osteosarcoma was readily identified.
This osteosarcoma specific gene expression signature was detect-
able in pulmonary metastases. Additionally, lists of genes which
discriminate osteosarcoma and Ewing’s sarcoma were developed.
Inspection of these gene lists identify a number of signal trans-
duction and cell cycle genes utilized differentially by these two
cancers.
Conclusion: Several genes expressed by osteosarcoma have poten-
tial for development as targets for immunohistochemical detection
for diagnostic purposes.